Myositis-specific autoantibodies

Brain and Nerve

Volumn 65, Issue 4, 2013, Pages 449-460

  Fujimoto, Manabu ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Anti MDA5 antibody; Anti Mi 2 antibody; Anti synthetase antibody; Anti TIF1 antibody; Myositis specific autoantibody

Indexed keywords

AUTOANTIBODY; MYOSITIS SPECIFIC AUTOANTIBODY; TRANSFER RNA; UNCLASSIFIED DRUG;

ANTISYNTHETASE SYNDROME; ARTHRITIS; ARTICLE; CALCINOSIS; DERMATOMYOSITIS; HUMAN; INTERSTITIAL LUNG DISEASE; MYOSITIS; PHENOTYPE; RAYNAUD PHENOMENON;

ACYL COENZYME A; AGE DISTRIBUTION; AUTOANTIBODIES; AUTOANTIGENS; HUMANS; LUNG DISEASES, INTERSTITIAL; MYOSITIS;

EID: 84876325486     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Fujimoto M: Dermatomyositis: myositis-specific autoantibodies and skin manifestations. Clin Exp Neuroimmunol 3: 74-84, 2012
2. Gunawardena H, Betteridge ZE, McHugh NJ: Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 48: 607-612, 2009
3. Mammen AL: Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 7: 343-354, 2011
4. Nishikai M, Reichlin M: Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis: characterization of the Jo-1 antibody system. Arthritis Rheum 23: 881-888, 1980 (Pubitemid 10040117)
5. Mathews MB, Bernstein RM: Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 304: 177-179, 1983 (Pubitemid 13079148)
6. Rosa MD, Hendrick JP Jr, Lerner MR, Steitz JA, Reichlin M: A mammalian tRNAHis-containing antigen is recognized by the polymyositis-specific antibody anti-Jo-1. Nucleic Acids Res 11: 853-870, 1983
7. Targoff IN: Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 28: 859-890, viii, 2002
8. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK: Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138: 1464-1474, 2010
9. Hirakata M, Nagai S: Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 12: 501-508, 2000
10. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A: Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 190: 815-826, 1999
11. Howard OMZ, Dong HF, Yang D, Raben N, Nagaraju K, et al: Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 196: 781-791, 2002
12. Levine SM, Raben N, Xie D, Askin FB, Tuder R, et al: Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 auto-antibody-associated myositis. Arthritis Rheum 56: 2729-2739, 2007 (Pubitemid 47237292)
13. Reichlin M, Mattioli M: Description of a serological reaction characteristic of polymyositis. Clin Immunol Immunopathol 5: 12-20, 1976
14. Targoff IN, Reichlin M: The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 28: 796-803, 1985 (Pubitemid 15027334)
15. Komura K, Fujimoto M, Matsushita T, Kaji K, Kondo M, et al: Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci 40: 215-217, 2005 (Pubitemid 41728971)
16. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, et al: Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147: 391-398, 2011
17. Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW: Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 48: 2285-2293, 2003
18. Love LA, Weinberg CR, McConnaughey DR, Oddis CV, Medsger TA Jr, et al: Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum 60: 2499-2504, 2009
19. Burd CJ, Kinyamu HK, Miller FW, Archer TK: UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem 283: 34976-34982, 2008
20. Kashiwagi M, Morgan BA, Georgopoulos K: The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development 134: 1571-1582, 2007 (Pubitemid 46746309)
21. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, et al: Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201: 591-601, 2005 (Pubitemid 40289549)
22. Mammen AL, Casciola-Rosen LA, Hall JC, Christopher-Stine L, Corse AM, et al: Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 60: 3784-3793, 2009
23. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, et al: Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52: 1571-1576, 2005 (Pubitemid 40663949)
24. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, et al: RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 60: 2193-2200, 2009
25. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, et al: The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49: 433-440, 2010
26. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, et al: Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 49: 1726-1733, 2010
27. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, et al: The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 51: 1278-1284, 2012
28. Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, et al: Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 11: 223, 2010
29. Chen F, Wang D, Shu X, Nakashima R, Wang G: Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 32: 3909-3915, 2012
30. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L: The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65: 25-34, 2011
31. Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, et al: Brief report: association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum 64: 3736-3740, 2012
32. Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, et al: Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 51: 1563-1570, 2012
33. Muro Y, Sugiura K, Hoshino K, Akiyama M: Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) 51: 800-804, 2012
34. Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, et al: Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 158: 675-677, 2011
35. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, et al: Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46: 25-28, 2007 (Pubitemid 44932779)
36. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, et al: A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54: 3682-3689, 2006 (Pubitemid 44737181)
37. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, et al: Myositis-specific anti-155/140 autoantibodies target transcriptional intermediary factor 1 family proteins. Arthritis Rheum 64: 513-522, 2012
38. Satoh M, Chan JY, Ross SJ, Li Y, Yamasaki Y, et al: Autoantibodies to transcription intermediary factor (TIF) 1beta associated with dermatomyositis. Arthritis Res Ther 14: R79, 2012
39. Muro Y, Ishikawa A, Sugiura K, Akiyama M: Clinical features of anti-TIF1-alpha antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-gamma or anti-Mi-2 autoantibodies. Rheumatology (Oxford) 51: 1508-1513, 2012
40. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, et al: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357: 96-100, 2001 (Pubitemid 32094911)
41. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G: Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med 134: 1087-1095, 2001
42. Stockton D, Doherty VR, Brewster DH: Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85: 41-45, 2001 (Pubitemid 32695714)
43. Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, et al: Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 12: R70, 2010
44. So MW, Koo BS, Kim YG, Lee CK, Yoo B: Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol 38: 2432-2435, 2011
45. Azuma K, Yamada H, Ohkubo M, Yamasaki Y, Yamasaki M, et al: Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 21: 178-183, 2011
46. Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O'Callaghan A, Martinez-Gómez X, Bosch X, et al: Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 64: 523-532, 2012
47. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG: The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66: 1345-1349, 2007 (Pubitemid 47492479)
48. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, et al: Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 47: 324-328, 2008 (Pubitemid 351267200)
49. Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, et al: Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 60: 1807-1814, 2009
50. Visual Dermatology 11: 830-831A, 2012
51. Allton K, Jain AK, Herz HM, Tsai WW, Jung SY, et al: Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A 106: 11612-11616, 2009
52. Khetchoumian K, Teletin M, Tisserand J, Herquel B, Ouararhni K, et al: Trim24 (Tif1 alpha): an essential 'brake' for retinoic acid-induced transcription to prevent liver cancer. Cell Cycle 7: 3647-3652, 2008
53. Vincent DF, Yan KP, Treilleux I, Gay F, Arfi V, et al: Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet 5: e1000575, 2009
54. Targoff IN, Trieu EP, Levy-Neto M, Fertig N, Oddis CV: Sera with autoantibodies to the MJ antigen react with NXP2 [abstract]. Arthritis Rheum 56: S787, 2007
55. Oddis CV, Fertig N, Goel A, Espada G, Confalone Gregorian M, et al: Clinical and serological characterization of the anti-MJ antibody in childhood myositis [abstract]. Arthritis Rheum 40: S139, 1997
56. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV: Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 36: 2547-2551, 2009
57. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, et al: Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71: 710-713, 2012
58. Ishikawa A, Muro Y, Sugiura K, Akiyama M: Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford) 51: 1181-1187, 2012
59. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, et al: Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 14: R97, 2012
60. Tansley S, Betteridge Z, Gunawardena H, Wedderburn LR, Chinoy H, et al: Clinical differences between adult and juvenile dermatomyositis associated with anti-NXP2 autoantibodies. Arthritis Rheum 64: S98, 2012
61. Fiorentino D, Christopher-Stine L, Chung L, Lingala B, Mammen AL, et al: Antibodies to NXP-2 and transcriptional intermediary factor-gamma identify patients with cancer-associated dermatomyositis. Arthritis Rheum 64: S842, 2012
62. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N: Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 56: 3132-3137, 2007 (Pubitemid 47502761)
63. Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, et al: Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis- specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 68: 1621-1625, 2009
64. Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, et al: Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods 384: 128-134, 2012
65. Fujimoto M, Matsushita T, Hamaguchi Y, Kaji K, Asano Y, et al: Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis 72: 151-153, 2013
66. Reeves WH, Nigam SK, Blobel G: Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A 83: 9507-9511, 1986 (Pubitemid 17223389)
67. Targoff IN, Johnson AE, Miller FW: Antibody to signal recognition particle in polymyositis. Arthritis Rheum 33: 1361-1370, 1990 (Pubitemid 20365567)
68. Miller T, Al-Lozi MT, Lopate G, Pestronk A: Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73: 420-428, 2002
69. Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, et al: anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65: 1635-1638, 2006 (Pubitemid 44799678)
70. Rouster-Stevens KA, Pachman LM: Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 35: 927-929, 2008 (Pubitemid 351747139)
71. Suzuki S, Ohta M, Shimizu Y, Hayashi YK, Nishino I: Anti-signal recognition particle myopathy in the first decade of life. Pediatr Neurol 45: 114-116, 2011
72. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, et al: A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62: 2757-2766, 2010
73. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al: Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63: 713-721, 2011
74. Mammen AL, Gaudet D, Brisson D, Christopher-Stine L, Lloyd TE, et al: Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 64: 1233-1237, 2012
75. Salajegheh M, Lam T, Greenberg SA: Autoantibodies against a 43 kDa muscle protein in inclusion body myositis. PLoS One 6: e20266, 2011